The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across age and no...

Descripción completa

Detalles Bibliográficos
Autores principales: Iles, Kathleen, Roberson, Mya L., Spanheimer, Philip, Gallagher, Kristalyn, Ollila, David W., Strassle, Paula D., Downs-Canner, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888624/
https://www.ncbi.nlm.nih.gov/pubmed/35232996
http://dx.doi.org/10.1038/s41523-022-00394-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888624/
https://www.ncbi.nlm.nih.gov/pubmed/35232996
http://dx.doi.org/10.1038/s41523-022-00394-1

Ejemplares similares